Andere Sprachen Ligand Pharmaceuticals Incorporated

Aktien

A1C9RN

US53220K5048

LGND

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
69.89 ^USD	-0.81%		-.--%	-2.14%

08.04.	Ligand Pharmaceuticals Incorporated gibt neue Daten zur Topiram-Injektion bekannt, die auf der 9. Konferenz des London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures vorgestellt wurden	CI
03.04.	Ligand Pharmaceuticals ernennt Scott Plesha zum Chief Executive Officer	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024	23.04.
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K	19.04.
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08.04.
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08.04.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI	04.04.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™	03.04.
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	03.04.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	03.04.
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference	05.03.
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	05.03.
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.03.
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	27.02.
Ligand: Q4 Earnings Snapshot	27.02.
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	27.02.
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	27.02.
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	27.02.
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27.02.
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	22.02.
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	19.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ligand Pharmaceuticals Incorporated

Aktien

A1C9RN

US53220K5048

LGND

Andere Sprachen

Filter